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Downregulation of Ca2 and Mg2 Transport Proteins in the
Kidney Explains Tacrolimus (FK506)-Induced Hypercalciuria
and Hypomagnesemia
TOM NIJENHUIS, JOOST G.J. HOENDEROP, and RENE´ J.M. BINDELS
Department of Physiology, Nijmegen Center for Molecular Life Sciences, University Medical Center
Nijmegen, Nijmegen, the Netherlands
Abstract. FK506 (tacrolimus) and dexamethasone are potent
immunosuppressants known to induce significant side effects
on mineral homeostasis, including hypercalciuria and hypo-
magnesemia. However, the underlying molecular mechanisms
remain unknown. The present study investigated the effects of
FK506 and dexamethasone on the expression of proteins in-
volved in active Ca2 reabsorption: the epithelial Ca2 channel
TRPV5 and the cytosolic Ca2-binding protein calbindin-
D28K. In addition, the renal expression of the putative Mg2
channel TRPM6, suggested to be involved in transcellular
Mg2 reabsorption, was determined. Administration of FK506
to rats by daily oral gavage during 7 d significantly enhanced
the urinary excretion of Ca2 and Mg2 and induced a signif-
icant hypomagnesemia. FK506 significantly decreased the re-
nal mRNA expression of TRPV5 (62  7% relative to con-
trols), calbindin-D28K (9  1%), and TRPM6 (52  8%), as
determined by real-time quantitative PCR analysis. Further-
more, semiquantitative immunohistochemistry showed re-
duced renal protein abundance of TRPV5 (24  5%) and
calbindin-D28K (29  4%), altogether suggesting that down-
regulation of these transport proteins is responsible for the
FK506-induced Ca2 and Mg2 wasting. In contrast, dexa-
methasone significantly enhanced renal TRPV5 (150  15%),
calbindin-D28K (177  23%), and TRPM6 (156  20%)
mRNA levels along with TRPV5 (211  8%) and calbindin-
D28K (176  5%) protein abundance in the presence of signif-
icantly increased Ca2 and Mg2 excretion. This indicated that
these proteins are directly or indirectly regulated by dexameth-
asone. In conclusion, FK506 and dexamethasone induce renal
Ca2 and Mg2 wasting, albeit by different mechanisms.
Downregulation of specific Ca2 and Mg2 transport proteins
provides a molecular mechanism for FK506-induced hypercal-
ciuria and hypomagnesemia, whereas dexamethasone posi-
tively regulates these proteins.
Immunosuppressants such as the calcineurin inhibitors cyclo-
sporin A and FK506 (tacrolimus) along with glucocorticoids
such as dexamethasone are widely prescribed in numerous
disorders and to organ transplant recipients. Although their
immunosuppressive actions are achieved by distinct mecha-
nisms, FK506 and dexamethasone both are known to induce
significant side effects on mineral homeostasis. These drugs
are associated with an increased bone turnover, a negative
Ca2 balance and hypercalciuria, perturbations that can ulti-
mately result in osteoporosis (1–3). Furthermore, hypomag-
nesemia is a widely known additional side effect of FK506
treatment (4, 5). The kidney is crucial to both Ca2 and Mg2
homeostasis by providing the main excretory route for these
divalent ions. However, the exact mechanisms by which these
immunosuppressants provoke renal cation wasting are
unknown.
The hypercalciuria during treatment with these drugs has
been attributed to increased bone resorption as well as de-
creased renal Ca2 reabsorption (2, 6, 7). In the kidney, the
bulk of Ca2 reabsorption is accomplished by Na-driven
passive paracellular Ca2 transport in the proximal tubule and
thick ascending limb of Henle (TAL) (8). Fine-tuning of Ca2
excretion is achieved by active transcellular reabsorption of
Ca2 in the distal convoluted tubule (DCT) and connecting
tubule (CNT), which involves apical Ca2 entry through the
epithelial Ca2 channel TRPV5 (previously ECaC1), intracel-
lular buffering and facilitated diffusion by the Ca2-binding
protein calbindin-D28K, and basolateral extrusion by the Na/
Ca2 exchanger (NCX1) and the plasma membrane Ca2
ATPase (PMCA1b) (9, 10). Theoretically, inhibition of active
Ca2 reabsorption could be involved in the immunosuppres-
sant-induced hypercalciuria.
FK506 treatment has been associated with an inappropri-
ately high fractional excretion of Mg2, suggesting that inhi-
bition of passive or active Mg2 reabsorption could contribute
to the hypomagnesemia (11). Active reabsorption of Mg2 has
been localized to the DCT, but in contrast to Ca2 reabsorp-
tion, little is known about the specific proteins that mediate
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transcellular Mg2 transport (12, 13). Recently, it was shown
that autosomal recessive hypomagnesemia, characterized by
disturbed intestinal Mg2 absorption and inappropriately high
fractional Mg2 excretion rates, is caused by mutations in the
gene encoding TRPM6 (14, 15). Like other ion channels in the
transient receptor potential (TRP) family, this protein contains
six transmembrane domains and is highly homologous to the
Mg2-permeable ion channel TRPM7, and TRPM6 mRNA
expression was detected in kidney and intestine (15). Recently,
we demonstrated that TRPM6 confines a Mg2 permeable
channel that is exclusively expressed in the apical membrane of
mouse DCT and small intestine, suggesting that TRPM6 con-
stitutes the apical Mg2 entry channel in transcellular Mg2
(re)absorption (16). The identification of TRPM6 provides an
important tool to study renal active Mg2 transport during
FK506 treatment on a molecular level.
Taken together, the cascade of cellular and molecular events
that lead to impaired renal Ca2 and Mg2 handling during
FK506 and glucocorticoid treatment is largely unknown. Hy-
pothetically, downregulation of Ca2 and Mg2 transport pro-
teins in the distal part of the nephron may be involved in the
pathogenesis of hypercalciuria and hypermagnesuria during
drug treatment. The aim of the present study, therefore, was to
determine the effects of FK506 and dexamethasone on the
expression of the Ca2 transport proteins TRPV5 and calbi-
ndin-D28K and the putative Mg2 channel TRPM6 in the
kidney. To this end, rats were treated for 7 d with these
immunosuppressants and housed in metabolic cages to collect
samples for urine analysis. Subsequently, expression levels of
TRPV5, calbindin-D28K, and TRPM6 were determined by real-
time quantitative PCR and immunohistochemical analysis.
Materials and Methods
Animal Studies
Young adult male Wistar rats with an initial weight of 225 to 250 g
were housed individually in metabolic cages to collect 24-h urine
samples. The animals were kept in a light- and temperature-controlled
room with ad libitum access to standard pelleted diet and water. The
animals were randomly assigned to either the control group (n  10)
or the two treatment groups, receiving FK506 (n  6) or dexameth-
asone (n  6). These immunosuppressants were dissolved in peanut
oil and administered daily by oral gavage. Control animals received
vehicle only, whereas the two treatment groups received either FK506
(Fujisawa Pharmaceutical Co., Osaka, Japan) at a single dose of 1
mg/d or dexamethasone (Sigma-Aldrich, Zwijndrecht, the Nether-
lands) at 300 g/d. Animals were treated for 7 d, after which blood
samples were taken and the animals were killed. Kidney cortex and
duodenum were sampled and immediately frozen in liquid nitrogen. In
addition, kidney cortex was fixed for immunohistochemistry by im-
mersion in 1% (wt/vol) periodate-lysine-paraformaldehyde for 2 h and
15% (wt/vol) sucrose in PBS overnight (17). Subsequently, samples
were stored at 80°C until further processing. The animal ethics
board of the University Medical Center Nijmegen approved all ex-
perimental procedures.
Analytical Procedures
Serum and urine Ca2 concentrations were determined using a
colorimetric assay as described previously (18). Serum and urine
[Mg2], [Na], [creatinine] [glucose], alkaline phosphatase, and
-glutamyl transpeptidase were measured on a Hitachi autoanalyzer
(Hitachi Corp., Tokyo, Japan).
Real-Time Quantitative PCR
Total RNA was extracted from kidney cortex and duodenum using
Trizol Total RNA Isolation Reagent (Life Technologies BRL, Breda,
the Netherlands). The obtained RNA was subjected to DNAse treat-
ment to prevent genomic DNA contamination. Thereafter, 2 g of
RNA was reverse transcribed by Moloney-murine leukemia virus-
reverse transcriptase (Life Technologies BRL) as described previ-
ously (19). The obtained cDNA was used to determine TRPV5,
calbindin-D28K, and TRPM6 mRNA levels in kidney cortex as well as
TRPV6, calbindin-D9K, and TRPM6 mRNA expression in duodenum.
Expression levels were quantified by real-time quantitative PCR on an
ABI Prism 7700 Sequence Detection System (PE Biosystems, Rot-
kreuz, Switzerland). PCR primers and fluorescence probes were de-
signed using the computer program Primer Express (Applied Biosys-
tems, Foster City, CA) and are listed in Table 1 (Biolegio, Malden, the
Netherlands).
Immunohistochemistry
Immunohistochemical staining was performed as described previ-
ously (17). In short, either single or double staining of sections for
TRPV5, calbindin-D28K, kallikrein, and the Na-Cl- co-transporter
(NCC) was performed on 7-m sections of fixed frozen kidney
samples. TRPV5 staining involved immersion of the kidney sections
in boiled citrate target retrieval buffer (0.01 M sodium citrate and 0.01
M citric acid [pH 6.0]), which was then left to cool for 30 min and
subsequent incubation in 0.3% (vol/vol) H2O2 in buffer (0.15 M NaCl,
0.1 M Tris-HCl [pH 7.5]) for 30 min. Sections were incubated for 16 h
at 4°C with primary antibody, affinity-purified guinea pig TRPV5
antibody (1:1000) (17), mouse anti–calbindin-D28K (Swant, Bell-
inzona, Switzerland; 1:500), rabbit anti-NCC (1:300) (20), and rabbit
anti-kallikrein (1:5000; Calbiochem, San Diego, CA). After incuba-
tion with biotin-coated goat anti–guinea pig secondary antibody,
TRPV5 was visualized using a tyramide signal amplification kit (NEN
Life Science Products, Zaventem, Belgium). For detection of calbi-
ndin-D28K, NCC, and kallikrein, sections were incubated with an
Alexa 488–conjugated goat anti-rabbit or an Alexa 594–conjugated
goat anti-mouse secondary antibody. Images were made using a Zeiss
fluorescence microscope equipped with a digital photo camera (Nikon
DMX1200). For semiquantitative determination of protein levels,
images were analyzed with the Image Pro Plus 4.1 image analysis
software (Media Cybernetics, Silver Spring, MD), resulting in quan-
tification of the protein levels as the mean of integrated optical
density.
Statistical Analyses
Data are expressed as means  SEM. Statistical comparisons were
tested by one-way ANOVA and Fisher multiple comparison. P 0.05
was considered statistically significant. Statistical analysis was per-
formed using the Statview Statistical Package software (Power PC
version 4.51; Berkeley, CA) on a Macintosh computer.
Results
Body Weight, Urine, and Serum Analysis
Net urinary excretion of Ca2 and Mg2 is depicted in
Figure 1. Additional biochemical analysis of the serum and
24-h urine samples of the experimental groups is shown in
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Table 2. In the FK506 group, net and fractional excretion of
Ca2 and Mg2 was significantly enhanced. Na excretion
was reduced in this treatment group, whereas urine volume did
not significantly differ from controls. Although serum Ca2
and Na levels were unaffected, FK506 treatment induced a
striking hypomagnesemia. Dexamethasone administration en-
hanced urinary Ca2 as well as Mg2 excretion. Likewise,
Na excretion and urine volume were significantly increased.
In the dexamethasone-treated animals, serum Ca2 levels did
not significantly differ from controls, whereas serum Na
levels were decreased. Serum Mg2 levels were significantly
reduced relative to controls but remained within the normal
range. Both serum creatinine and GFR, as determined by
creatinine clearance, did not significantly differ from controls
in both the FK506 and dexamethasone groups. Serum glucose
levels were significantly increased in both the FK506- and
dexamethasone-treated groups, resulting in increased glucose
excretion in the dexamethasone group only. In addition, uri-
nary excretion of markers of tubular damage (alkaline phos-
phatase and -glutamyl transpeptidase) was detectable, albeit
not significantly increased in the FK506 group, whereas the
dexamethasone-treated group showed significant enzymuria
(21). Although baseline body weight did not differ signifi-
cantly between the groups (data not shown), at the end of the
experiment, dexamethasone-treated animals had a significantly
lower mean body weight compared with controls, whereas
FK506 treatment did not affect body weight.
Renal mRNA Expression Levels of TRPV5, Calbindin-
D28K, and TRPM6
For evaluating the possible association between increased
urinary excretion of Ca2 and Mg2 and the expression levels
of the respective transport proteins, renal mRNA levels of the
epithelial Ca2 channel TRPV5, the cytosolic Ca2-binding
protein calbindin-D28K and the putative epithelial Mg2 chan-
nel TRPM6 were determined by real-time quantitative PCR
analysis. FK506 significantly decreased TRPV5, calbindin-Ta
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Figure 1. Effect of FK506 and dexamethasone treatment on net
urinary Ca2 and Mg2 excretion in the rat. Net excretion of Ca2
and Mg2 was determined by analysis of 24-h urine samples of rats
individually housed in metabolic cages. Ctr, controls; FK506, FK506
1 mg/d by oral gavage; Dex, dexamethasone 300 g/d by oral gavage.
Data are presented as means  SEM. **P  0.05 versus controls.
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D28K, and TRPM6 mRNA levels in the kidney (Figure 2).
Conversely, dexamethasone treatment significantly enhanced
the renal mRNA expression of both Ca2 transport proteins
and TRPM6.
Renal Protein Abundance of TRPV5 and Calbindin-
D28K
For assessing whether the changes in renal mRNA levels
resulted in altered protein expression, TRPV5 and calbindin-
D28K protein abundance was semiquantified by immunohisto-
chemistry (Figure 3A). These results illustrated that the above-
mentioned mRNA results were indeed accompanied by similar
effects on the protein level. Computerized analysis of the
immunohistochemical staining showed significantly reduced
TRPV5 and calbindin-D28K protein expression during FK506
treatment, whereas dexamethasone significantly enhanced the
abundance of these Ca2 transport proteins in the kidney
(Figure 3B). Of note, the effects on TRPV5 protein expression
were more pronounced compared with the mRNA level, sug-
gesting that in addition to affecting gene transcription, addi-
tional translational changes might have occurred.
For confirming the specificity of the observed effects on
the Ca2 and Mg2 transport proteins, protein abundance of
kallikrein and NCC were determined by immunohistochem-
istry (Figure 3A). The renal abundance of tissue kallikrein,
a specific marker for the DCT and CNT (22), did not
significantly differ from controls in both the FK506 and
dexamethasone groups (Figure 3B). In addition, the protein
expression of NCC, exclusively expressed in the DCT, was
not significantly affected by FK506 treatment but showed a
Figure 2. Effect of FK506 and dexamethasone on mRNA expression levels of Ca2 and Mg2 transport proteins in the rat kidney. Renal mRNA
expression levels of the epithelial Ca2 channel TRPV5, the cytosolic Ca2-binding protein calbindin-D28K (CaBP28), and the putative Mg2
channel TRPM6 were determined by real-time quantitative PCR analysis. Ctr, controls; FK506, FK506 1 mg/d by oral gavage; Dex,
dexamethasone 300 g/d by oral gavage. Data are presented as means  SEM. **P  0.05 versus controls.
Table 2. Urine and serum analyses and body weighta
Controls FK506 Dexamethasone
Urine
FE Ca2 (%) 0.62  0.07 1.08  0.17b 1.02  0.11b
FE Mg2 (%) 4.7  1.1 35.1  3.4b 20.4  2.2b
Na excretion (mmol/24 h) 1.6  0.1 1.0  0.2b 2.4  0.2b
FE Na (%) 0.64  0.06 0.46  0.04b 1.15  0.05b
glucose excretion (mmol/24 h) 0.1  0.1 2.7  1.3 20.8  4.8b
diuresis (ml/24 h) 8.8  1.0 18.6  4.8 42.5  6.2b
Ccr (ml/min) 1.1  0.1 1.1  0.1 1.1  0.1b
ALP excretion (U/24 h) 0.1  0.1 0.4  0.2 1.1  0.4b
-GT excretion (U/24 h) 0.1  0.1 1.3  0.7 4.9  2.5b
Serum
Ca2 (mmol/L) 2.53  0.03 2.51  0.03 2.49  0.02b
Mg2 (mmol/L) 1.01  0.02 0.65  0.02b 0.92  0.01b
Na (mmol/L) 142.1  0.5 141.0  0.4 134.0  0.5b
glucose (mmol/L) 6.9  0.2 11.1  0.9b 18.7  2.4b
creatinine (mol/L) 37  1 38  1 42  2
Body weight (g) 310  9.3 296  6.1 277  9.7b
a Controls, animals receiving vehicle only; FK506, FK506 1 mg/d; Dexamethasone, dexamethasone 300 g/d; FE, fractional excretion;
Ccr, creatinine clearance; ALP, alkaline phosphatase; -GT, gamma-glutamyl transpeptidase. Data are presented as means  SEM.
b P  0.05 versus controls.
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significant, albeit modest, increase in the dexamethasone-
treated animals (Figure 3B). Furthermore, no signs of a
general deleterious effect of FK506 (inclusion bodies, tubu-
lar vacuolization, and atrophy) were detected on light mi-
croscopic analysis (4). GFR was unaffected and enzymuria
was not significantly increased, although markers of tubular
damage were detectable. Importantly, the unaltered expres-
sion of kallikrein and NCC suggested that no overt FK506
nephrotoxicity was present in DCT.
In addition, co-staining of kidney sections for the presence
of TRPV5 and kallikrein was performed, which showed a full
co-localization of these proteins in DCT and CNT in the
control animals (Figure 4A). Importantly, Figure 4B clearly
illustrates that TRPV5 protein abundance in DCT and CNT is
significantly reduced in the FK506-treated animals, whereas
kallikrein expression levels are not affected. Dexamethasone
treatment did not influence the co-localization of TRPV5 and
kallikrein, substantiating that the dexamethasone-induced in-
crease of TRPV5 abundance is confined to these nephron
segments (Figure 4C). Co-staining of kidney sections for kal-
likrein and calbindin-D28K showed similar results, with the
exception that calbindin-D28K expression extended further into
the cortical collecting duct (data not shown).
Intestinal mRNA Expression Levels of TRPV6,
Calbindin-D9K, and TRPM6
Theoretically, upregulation of Ca2 transport proteins in the
intestine could contribute to the increased Ca2 wasting, and
decreased intestinal TRPM6 expression could contribute to the
hypomagnesemia. Therefore, the duodenal mRNA expression
of the epithelial Ca2 channel TRPV6, the cytosolic Ca2-
binding protein calbindin-D9K, and TRPM6 were determined
(Figure 5). mRNA expression of all three transporters was not
significantly altered by FK506 treatment. Dexamethasone sig-
nificantly increased TRPV6 and calbindin-D9K mRNA expres-
sion levels, whereas TRPM6 mRNA expression was not sig-
nificantly affected.
Discussion
The present study demonstrated that FK506 and dexameth-
asone significantly enhance renal Ca2 and Mg2 excretion,
albeit by different molecular mechanisms. The decreased ex-
pression of the Ca2 transport proteins TRPV5 and calbindin-
D28K and the putative Mg2 channel TRPM6 during FK506
treatment suggested that downregulation of these transport
proteins contributes to the pathogenesis of FK506-induced
hypercalciuria and hypomagnesemia. In contrast, dexametha-
Figure 3. Effect of FK506 and dexamethasone on protein abundance in the rat kidney. (A) Representative images showing kidney sections
stained for the epithelial Ca2 channel TRPV5, the cytosolic Ca2-binding protein calbindin-D28K (CaBP28), kallikrein, and the Na-Cl
cotransporter (NCC). (B) Protein abundance was determined by computerized analysis of immunohistochemical images and is presented as
integrated optical density (IOD; arbitrary units). Ctr, controls; FK506, FK506 1 mg/d by oral gavage; Dex, dexamethasone 300 g/d by oral
gavage. Data are presented as means  SEM. **P  0.05 versus controls.
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sone treatment increased renal expression levels of TRPV5,
calbindin-D28K, and TRPM6, indicating that these transport
proteins are either directly or indirectly regulated by
dexamethasone.
FK506 treatment significantly increased urinary Ca2 ex-
cretion, accompanied by a downregulation of the renal mRNA
expression of TRPV5 and calbindin-D28K and a specific reduc-
tion of the protein abundance of these Ca2 transport proteins
in DCT and CNT, recognized as the main sites of transcellular
Ca2 reabsorption. Previous reports showed reduced calbi-
ndin-D28K levels during FK506 treatment, suggesting that
FK506 could affect active Ca2 transport (23). That serum
Ca2 concentrations and GFR did not differ from controls
confirmed that impaired Ca2 reabsorption rather than an
increased filtered load caused the hypercalciuria. Morphologic
features of tubular toxicity were not detected. Furthermore, the
excretion of urinary markers of tubular damage was not sig-
nificantly increased and the expression of specific markers for
DCT and CNT was unaltered, excluding that a general delete-
rious effect of FK506 on DCT is responsible for the observed
downregulation. In addition, the expression of the major intes-
tinal Ca2 transport proteins was not increased by FK506
treatment, excluding that hypercalciuria is secondary to up-
regulation of active Ca2 absorption. The present data strongly
supported our hypothesis that FK506 induces a primary defect
of renal active Ca2 reabsorption by specifically downregulat-
ing the proteins involved in active Ca2 transport.
The molecular mechanism underlying the downregulation of
the Ca2 transport proteins by FK506 remains elusive. In
previous studies, plasma calcitriol (1,25(OH)2D3) was either
unaltered or moderately increased, whereas plasma parathyroid
levels were not affected by similar doses of FK506, which
excludes that the reduced Ca2 transport protein expression
levels are secondary to decreased circulating levels of these
calcitropic hormones (11, 23, 24). The immunosuppressive
action of FK506 depends on the inhibition of the Ca2-depen-
dent phosphatase calcineurin in T lymphocytes (25–27). Cal-
cineurin is not known to be involved in renal Ca2 reabsorp-
tion, but another calcineurin inhibitor, cyclosporine A,
increased urinary Ca2 excretion and decreased calbindin-
D28K protein levels, suggesting that calcineurin inhibition may
play a role in the impairment of Ca2 reabsorption by these
drugs (23, 28). In addition, FK506 binds to intracellular im-
munophilins called FK506-binding proteins (FKBP), which
have been implicated as ion channel regulators (29–31). In
particular, FKBP4 was shown to bind and regulate the Ca2-
permeable Drosophila TRPL channel, and this binding was
disrupted by the addition of FK506 (32). Furthermore, several
intracellular Ca2-release channels were shown to be modu-
lated by binding and dissociation of FKBP (33–35). Therefore,
it is tempting to speculate that FKBP are potential associated
proteins regulating TRPV5 expression or activity.
Hypomagnesemia is a widely known adverse effect of
FK506 treatment (4, 5). The increased fractional excretion of
Mg2 in the presence of a profound hypomagnesemia indi-
cated that renal Mg2 reabsorption is seriously impaired by
FK506. This renal Mg2 wasting was accompanied by reduced
renal expression of the putative Mg2 channel TRPM6. Mu-
tations in the gene encoding TRPM6 were recently shown to
cause hereditary hypomagnesemia, which was also accompa-
nied by an inappropriately increased fractional excretion of
Mg2 (14, 15). Importantly, RT-PCR analysis of microdis-
sected rat nephrons showed strong TRPM6 expression in the
DCT, the main site of active Mg2 reabsorption (15). Together
with the high structural homology to TRPM7, which has been
previously identified to constitute a Mg2 permeable cation
channel, these data indicated that this protein constitutes the
Figure 4. Co-immunohistochemical staining of rat kidney for the
epithelial Ca2 channel TRPV5 and kallikrein. Co-staining of kidney
sections for TRPV5 and kallikrein, a marker for the distal convoluted
tubule (DCT) and connecting tubule (CNT), in controls (A), FK506-
treated animals (B), and dexamethasone-treated animals (C). Controls,
rats receiving vehicle only; FK506, rats receiving FK506 1 mg/d by
oral gavage; Dexamethasone, rats receiving dexamethasone 300 g/d
by oral gavage.
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apical Mg2 entry channel in renal transcellular Mg2 trans-
port in DCT (36, 37). Of note, the DCT has been previously
indicated as a possible site of the tubular Mg2 leak during
FK506 treatment (13). The duodenal TRPM6 mRNA levels
were not significantly altered by FK506 treatment, which is at
variance with primary role of duodenal TRPM6 in the patho-
genesis of hypomagnesemia. Altogether, our data showed that
in addition to mutations in TRPM6, drug-induced downregu-
lation of this ion channel in kidney is associated with increased
urinary Mg2 excretion and hypomagnesemia, further substan-
tiating the importance of TRPM6 in renal Mg2 reabsorption.
Dexamethasone-treated animals displayed a significant hy-
percalciuria, but, in contrast to FK506 treatment, dexametha-
sone increased the expression levels of TRPV5 and calbindin-
D28K. However, in line with previous data that showed
decreased tubular reabsorption of Ca2 during glucocorticoid
treatment, the unaltered serum Ca2 levels and GFR suggested
that a primary impairment of Ca2 reabsorption is responsible
for the hypercalciuria observed in our study (2, 6). In the
proximal tubule and TAL, passive reabsorption of Ca2 takes
place, which is altogether responsible for reabsorbing approx-
imately 70 to 90% of the filtered Ca2 (8). In this paracellular
pathway, Ca2 is transported down an electrochemical gradi-
ent that is dependent on Na reabsorption, and impairment of
the latter is known to result in increased Ca2 excretion. In this
study, net Na excretion was indeed considerably increased
and serum Na levels were reduced, whereas NCC expression
was enhanced. Previously, glucocorticoid excess was demon-
strated to enhance the expression of the distally located NCC
and epithelial Na channel, whereas dexamethasone was
shown to inhibit the function and expression of the proximal
tubular Na/phosphate co-transporter (38–41). Therefore, re-
duced reabsorption of Na in the proximal tubule or TAL
could be responsible for the increased Na excretion and, by
decreasing passive Ca2 reabsorption, the dexamethasone-in-
duced hypercalciuria. In addition, enzymuria was significantly
increased by dexamethasone, suggesting that structural damage
to the proximal tubule or TAL could contribute to the increased
Na and Ca2 excretion. The increased expression of the
proteins involved in active Ca2 transport in DCT indicated
that these proteins are directly or indirectly regulated by dexa-
methasone. The latter might reflect a compensatory effect
secondary to the increased distal Ca2 load, similar to the
increased expression of distally located Na transporters,
which has been shown after inhibition of Na reabsorption in
the loop of Henle (42–44). The concomitant increase in ex-
pression of the major intestinal Ca2 transport proteins sug-
gests a direct stimulatory effect of dexamethasone on active
Ca2 (re)absorption in kidney and intestine.
It is interesting that dexamethasone treatment resulted in an
increased urinary excretion of Mg2 with a concomitant decrease
of serum Mg2 levels. However, the latter effect was much
smaller than that observed in the FK506-treated animals and
remained within the normal range, possibly because of the milder
renal Mg2 leak. Alternatively, increased intestinal Mg2 absorp-
tion mediated by upregulated intestinal TRPM6 expression levels
might counterbalance renal Mg2 losses, but this is not supported
by the present study. In analogy to Ca2 reabsorption, a substan-
tial part of Mg2 filtered by the glomerulus is reabsorbed via the
paracellular Na-driven pathway (12). Therefore, impairment of
the passive reabsorption of divalent ions in proximal tubule and
TAL could explain both the hypercalciuria and hypermagnesuria.
Subsequently, the enhanced TRPM6 expression levels could re-
sult from a direct stimulatory effect of dexamethasone or a com-
pensatory response, serving to limit the renal Mg2 wasting.
Indeed, serum glucose levels were significantly increased in
both the FK506- and dexamethasone-treated animals. In the
FK506-treated group, urinary glucose excretion did not signifi-
cantly differ from controls, but the trend toward increased glyco-
suria could very well explain the concomitant trend toward in-
creased urine volume. Furthermore, dexamethasone significantly
increased glycosuria, which in conjunction with the increased
Na excretion might cause the observed polyuria.
In conclusion, FK506-induced downregulation of Ca2 and
Mg2 transport proteins could be a critical factor in the patho-
genesis of hypercalciuria and hypomagnesemia. Elucidation of
the molecular mechanism responsible for these inhibitory effects
will extend our knowledge of the in vivo regulation of these
transporters and will identify novel targets for pharmacologic
therapy.
Figure 5. Effect of FK506 and dexamethasone treatment on mRNA expression of Ca2 and Mg2 transport proteins in rat duodenum. Duodenal
mRNA expression levels of the epithelial Ca2 channel TRPV6, the cytosolic Ca2-binding protein calbindin-D9K (CaBP9), and the putative
Mg2 channel TRPM6 were determined by real-time quantitative PCR analysis. Ctr, controls; FK506, FK506 1 mg/d by oral gavage; Dex,
dexamethasone 300 g/d by oral gavage. Data are presented as means  SEM. * P  0.05 versus controls.
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